Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad context, audiences have historically sought reliable, accessible explanations of drug mechanisms, side effects, and disease processes. This heritage provides a structured baseline for interpreting clinical phenomena, yet it often remains at a population-wide level, without drilling into specific exposure scenarios or occupational hazards. As we pivot from this general health framework toward a more targeted inquiry, the focus narrows to the clinical evidence review of Fosamax and its association with osteonecrosis of the jaw. This transition moves beyond abstract health literacy into a concrete risk assessment context, where the question of causation becomes paramount. The bridge concept here is the shift from passive receipt of general health information to active evaluation of a specific pharmaceutical exposure—Fosamax—and its documented link to a serious adverse outcome. This pivot acknowledges that while general health resources establish background knowledge, the occupational exposure concern demands a more granular, evidence-based scrutiny of patient histories, dosage regimens, and temporal relationships.

Clinical Background and Mechanism of Action

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover and remodeling. In the jaw, which has high bone turnover rates and is subject to microtrauma from chewing and dental procedures, this suppression may impair the ability to repair microdamage and maintain bone health, potentially leading to necrosis. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Osteonecrosis of the Jaw: Definition and Risk Factors

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ involves exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, and impaired healing after dental procedures. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other causes.

Temporal Relationship and Causation Considerations

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, excluding other causes such as cancer, radiation therapy, or other medications. The presence of known risk factors, such as dental procedures or poor oral hygiene, may complicate the assessment of causation. The timeline of onset, which can range from days to months after starting the drug, supports a potential causal link in some cases. However, the similar incidence of symptoms in placebo-controlled trials suggests that not all cases are attributable to Fosamax.

Adequacy of Warnings and Clinical Management

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warning also notes that ONJ can occur spontaneously and is generally associated with dental procedures or infection. However, the warning does not provide specific guidance on screening or monitoring for ONJ in asymptomatic patients, nor does it quantify the absolute risk. The label advises discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to potentially reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management typically involves conservative measures, including oral hygiene, antibiotics, and avoidance of further dental surgery. Discontinuation of Fosamax may be considered, but the benefit of stopping the drug must be weighed against the risk of fracture from untreated osteoporosis. In summary, Fosamax is associated with a risk of ONJ, particularly in patients with additional risk factors such as dental procedures or prolonged use. The prescribing information includes warnings about this risk, but the absolute risk is not well-defined. Patients and healthcare providers should be aware of the potential for ONJ and consider preventive dental care before initiating bisphosphonate therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis. It works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism can suppress normal bone remodeling, particularly in the jaw, potentially leading to osteonecrosis of the jaw (ONJ) in some patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is the causal link between Fosamax and ONJ established?

Causation is assessed by establishing a temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer or radiation therapy. The timeline can range from days to months after starting the drug. However, similar symptom incidence in placebo-controlled trials indicates not all cases are attributable to Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What does the Fosamax label warn about ONJ?

The prescribing information includes a specific warning (Section 5.4) describing ONJ, associated risk factors, and increased risk with longer exposure. It notes that ONJ can occur spontaneously or after dental procedures, but does not provide screening guidance or quantify absolute risk. It advises discontinuation of bisphosphonate before invasive dental procedures to potentially reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.